Critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety
An article in the March edition of Vaccine explains why it is necessary to know the background rates of possible adverse events of special interest (AESI) when monitoring the safety of COVID-19 vaccines. The article provides examples to illustrate the use of background rates and discusses tools available from the Brighton Collaboration that facilitate case evaluation and understanding of AESI.